AllianceBernstein’s Prelude Therapeutics PRLD Stock Holding History

AllianceBernstein’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$36K	Buy	+10,530	New	+$45.8K	﹤0.01%	3307
2022 Q2	–	Sell	-21,500	Closed	-$148K	–	3353
2022 Q1	$148K	Sell	21,500 -1,968	-8%	-$18K	﹤0.01%	3056
2021 Q4	$292K	Buy	23,468 +9,768	+71%	+$159K	﹤0.01%	2950
2021 Q3	$428K	Sell	13,700 -4,200	-23%	-$136K	﹤0.01%	2814
2021 Q2	$512K	Buy	17,900 +7,500	+72%	+$267K	﹤0.01%	2799
2021 Q1	$451K	Buy	10,400 +1,800	+21%	+$119K	﹤0.01%	2701
2020 Q4	$615K	Buy	+8,600	New	+$428K	﹤0.01%	2496

Other funds holding PRLD

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

AllianceBernstein's PRLD Position: Q2 2026 in Review

AllianceBernstein opened a new position in Prelude Therapeutics (PRLD) in Q2 2026: 10,530 shares worth $36K. The stake represents ﹤0.01% of the portfolio and ranks #3307 among its holdings. This is a return to the name: AllianceBernstein previously reported a position in PRLD as recently as Q1 2022.

AllianceBernstein first reported a position in PRLD in Q4 2020 and has held it in 7 quarters since. The position peaked at $615K in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q2 2026.

AllianceBernstein held 10,530 shares of Prelude Therapeutics worth $36K as of Q2 2026.
Prelude Therapeutics was a new AllianceBernstein position in Q2 2026.
Prelude Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #3307 holding.
AllianceBernstein first reported a position in Prelude Therapeutics in Q4 2020 and has held it in 7 quarters since.
AllianceBernstein's Prelude Therapeutics position peaked at $615K in Q4 2020.
75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.